Patients

Preclinical Phase 1 Phase 2 Phase 2b Phase 3
Systemic Sclerosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 2b Phase in progress
Phase 3 Phase not started
Cystic Fibrosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started
Dermatomyositis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started
Systemic Lupus Erythematosus
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started

Anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has generated positive data in Phase 2 studies in diffuse cutaneous systemic sclerosis, cystic fibrosis and dermatomyositis. Additionally, the Company is evaluating anabasum in open-label extension studies in systemic sclerosis and skin-predominant dermatomyositis. The Company expects to commence a Phase 2 study in systemic lupus erythematosus, a Phase 3 study in systemic sclerosis and a Phase 2b study in cystic fibrosis in the fourth quarter of 2017.

To learn more about each of our ongoing studies, please click on one of the below links.